Multicenter, Observational Cohort Study Evaluating Third-Generation Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia, and Citrobacter Species
Open Access
- 14 May 2020
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 9 (5), 254
- https://doi.org/10.3390/antibiotics9050254
Abstract
Objectives: There is debate on whether the use of third-generation cephalosporins (3GC) increases the risk of clinical failure in bloodstream infections (BSIs) caused by chromosomally-mediated AmpC-producing Enterobacterales (CAE). This study evaluates the impact of definitive 3GC therapy versus other antibiotics on clinical outcomes in BSIs due to Enterobacter, Serratia, or Citrobacter species. Methods: This multicenter, retrospective cohort study evaluated adult hospitalized patients with BSIs secondary to Enterobacter, Serratia, or Citrobacter species from 1 January 2006 to 1 September 2014. Definitive 3GC therapy was compared to definitive therapy with other non-3GC antibiotics. Multivariable Cox proportional hazards regression evaluated the impact of definitive 3GC on overall treatment failure (OTF) as a composite of in-hospital mortality, 30-day hospital readmission, or 90-day reinfection. Results: A total of 381 patients from 18 institutions in the southeastern United States were enrolled. Common sources of BSIs were the urinary tract and central venous catheters (78 (20.5%) patients each). Definitive 3GC therapy was utilized in 65 (17.1%) patients. OTF occurred in 22/65 patients (33.9%) in the definitive 3GC group vs. 94/316 (29.8%) in the non-3GC group (p = 0.51). Individual components of OTF were comparable between groups. Risk of OTF was comparable with definitive 3GC therapy vs. definitive non-3GC therapy (aHR 0.93, 95% CI 0.51–1.72) in multivariable Cox proportional hazards regression analysis. Conclusions: These outcomes suggest definitive 3GC therapy does not significantly alter the risk of poor clinical outcomes in the treatment of BSIs secondary to Enterobacter, Serratia, or Citrobacter species compared to other antimicrobial agents.Keywords
This publication has 28 references indexed in Scilit:
- Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line AgentsClinical Infectious Diseases, 2018
- Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysisJournal of Antimicrobial Chemotherapy, 2015
- Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?International Journal of Antimicrobial Agents, 2012
- AmpC β-LactamasesClinical Microbiology Reviews, 2009
- Emergence of Antibiotic Resistance during Therapy for Infections Caused by Enterobacteriaceae Producing AmpC β-Lactamase: Implications for Antibiotic UseAntimicrobial Agents and Chemotherapy, 2008
- Diagnosis and Treatment of Extended-Spectrum and AmpC β-Lactamase–Producing OrganismsAnnals of Pharmacotherapy, 2007
- Use of Several Inducer and Substrate Antibiotic Combinations in a Disk Approximation Assay Format To Screen for AmpC Induction in Patient Isolates of Pseudomonas aeruginosa , Enterobacter spp., Citrobacter spp., and Serratia sppJournal of Clinical Microbiology, 2005
- Bloodstream Infections Caused by Enterobacter Species: Predictors of 30-Day Mortality Rate and Impact of Broad-Spectrum Cephalosporin Resistance on OutcomeClinical Infectious Diseases, 2004
- Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter sppAntimicrobial Agents and Chemotherapy, 2001
- Enterobacter Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during TherapyAnnals of Internal Medicine, 1991